Hanmi Pharmaceutical Co., Ltd.

Hanmi Pharmaceutical Co. , Ltd. is a pharmaceutical company headquartered in Seoul, South Korea, dedicated to developing innovative drugs across various therapeutic areas, including oncology, diabetes, and cardiovascular diseases. Founded in 1973 in Seoul, South Korea, Hanmi Pharmaceutical Co.

, Ltd. focuses on the research, development, and commercialization of pharmaceuticals. The company's founder has a notable background, but specific details about their previous ventures are not available. Hanmi operates independently and has not undergone any significant mergers or changes in strategy since its inception.

Hanmi Pharmaceutical specializes in revolutionary treatments focused on oncology, diabetes, and cardiovascular conditions. Their portfolio includes proprietary medications designed to meet critical medical needs, such as a dual-action diabetes treatment. The company serves a global market, delivering products to healthcare providers and patients across the United States, Europe, and Asia, leveraging advanced research and development techniques for high-quality pharmaceutical solutions. In the most recent fiscal year 2024, Hanmi Pharmaceutical reported a revenue of USD 817.

41 bn and an EBITDA of USD 153. 51 bn, generated through a combination of B2B and direct-to-consumer sales of proprietary medications under exclusive licensing agreements. Hanmi Pharmaceutical is focused on expanding its product lineup, with plans to launch new innovative treatments in the near future. The company aims to penetrate additional markets in Europe and Asia by 2025, utilizing recent funding to support these development and expansion initiatives.

Specific details regarding the application of this funding are not publicly disclosed.